The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection.

TitleThe use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection.
Publication TypeJournal Article
Year of Publication2009
AuthorsLocke JE, Magro CM, Singer AL, Segev DL, Haas M, Hillel AT, King KE, Kraus E, Lees LM, Melancon JK, Stewart ZA, Warren DS, Zachary AA, Montgomery RA
JournalAm J Transplant
Volume9
Issue1
Pagination231-5
Date Published2009 Jan
ISSN1600-6143
KeywordsAdult, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Complement C5, Female, Graft Rejection, Humans, Immunoglobulins, Intravenous, Kidney Transplantation, Living Donors, Male, Salvage Therapy
Abstract

Desensitized patients are at high risk of developing acute antibody-mediated rejection (AMR). In most cases, the rejection episodes are mild and respond to a short course of plasmapheresis (PP) / low-dose IVIg treatment. However, a subset of patients experience severe AMR associated with sudden onset oliguria. We previously described the utility of emergent splenectomy in rescuing allografts in patients with this type of severe AMR. However, not all patients are good candidates for splenectomy. Here we present a single case in which eculizumab, a complement protein C5 antibody that inhibits the formation of the membrane attack complex (MAC), was used combined with PP/IVIg to salvage a kidney undergoing severe AMR. We show a marked decrease in C5b-C9 (MAC) complex deposition in the kidney after the administration of eculizumab.

DOI10.1111/j.1600-6143.2008.02451.x
Alternate JournalAm J Transplant
PubMed ID18976298
Related Faculty: 
Cynthia M. Magro, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700